HSR Act Waiting Period Expires for Eli Lilly Acquisition
CNTA has more than doubled off its 52-week low of $10.95 on light trading volume (0.3× avg).
Summary
Centessa Pharmaceuticals announced that a key regulatory hurdle for its acquisition by Eli Lilly has been cleared, bringing the deal closer to closing.
Key Events · M&A and Partnerships · CNTA
-
HSR Act Waiting Period Expires
The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 expired on May 21, 2026, satisfying a critical regulatory condition for the acquisition by Eli Lilly and Company.
-
Acquisition Progresses
This development moves the previously announced acquisition by Eli Lilly, valued at $38.00 per share plus a CVR, closer to completion.
-
Remaining Conditions
The acquisition is still subject to other customary closing conditions, including Centessa shareholder approval and sanction by the High Court of Justice of England and Wales.
Analysis · CNTA · Life Sciences
This 8-K announces the expiration of the Hart-Scott-Rodino (HSR) Act waiting period, a key regulatory condition for Eli Lilly's acquisition of Centessa Pharmaceuticals. This development is a positive step, reducing regulatory risk and moving the previously announced $38.00 per share cash-plus-CVR deal closer to completion. The stock is currently trading near its 52-week high, reflecting market confidence in the deal closing. The acquisition remains subject to shareholder approval and sanction by the UK High Court.
At the time of this filing, CNTA was trading at $39.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $10.95 to $40.26. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.